N/A N=77 Global Management of Facial Rejuvenation With a New Range of Hyaluronic Acid Dermal Fillers
Facial Wrinkles
Primary: Full Face Global Aesthetic Improvement — 2.5 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=101 Prospective Evaluation of Facial Cosmetic Procedures
Cosmetic Techniques
Primary: Patient Satisfaction With Validated FACE-Q Aesthetics Survey — 28.0; 24.0; 36.0; 36.0 score on a scale
Phase 4 N=25 Changing in Skin Physiology After Microdroplet Placement of Stabilized Hyaluronic Acid in Aging Faces
Aging
Primary: Hydration Level — 53.19; 46.75 AU (arbitrary unit) — p=<0.05
N/A N=143 Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area
Cosmetic Techniques
Primary: the Change in Dynamic Strain in the Glabella Area After Injection Over Time — 6.4; 10.9; 6.6; 8.9 percent difference of neutral+dyanamic
Phase 4 N=18 Rejuvenation of the Lower Eyelid Using a Combination of Two Hyaluronic Acid Fillers - a Pilot Study
Infraorbital Hollows
Primary: The Primary Objective of This Study is to Determine the Efficacy and Longevity of the Use of Restylane® and Perlane® in Combination for the Rejuvenation of the…
Phase 4 N=154 Study of BOTOX and JUVEDERM for Treatment of Moderate to Severe Facial Wrinkles and Folds
Wrinkles
Primary: Efficacy — 77; 74; 73; 72 participantes rated improved and higher
N/A N=60 Pan Facial Volume Restoration
Volume Loss (Soft Tissue Ptosis or Atrophy )
Primary: Mean Change From Baseline in Volume Loss Assessment — -0.8 Score on a scale
Phase 4 N=32 Juvederm Ultra With Lidocaine Compared With Restylane for the Correction of Nasolabial Folds
Nasolabial Folds
Primary: Procedural Pain Score — 2.0; 4.1 units on a scale
Phase 4 N=58 Sequential Treatment With BELKYRA® Then Juvéderm® VOLUMA™ With Lidocaine for Overall Improvement in Jawline Contour
Contour
Primary: Percentage of Participants Who Showed ≥ 1-point Jawline Improvement From Baseline on the Allergan Loss of Jawline Definition Scale (ALJDS), as Assessed by the…
Phase 3 N=26 Lateral Canthal Rhytides With Medium Depth Chemical Peel With or Without Pretreatment With Botulinum Toxin A
Wrinkles
Primary: Posttreament Results of Chemical Peel if Botox A is Added as Pre-treatment — 1; 2 Units on a wrinkle severity scale — p=.002
N/A N=20 Perioral Rejuvenation and Upper Lip Enhancement
Perioral Rejuvenation · Upper Lip Projection
Primary: Nasal Tip Projection — 0.601 ratio
Phase 4 N=30 Emervel for the Correction of Lower Face Wrinkles & Folds
Nasolabial Folds · Marionette Lines · Wrinkles
Primary: Number of Subjects With Naturalness of Expression in Motion (2D Video) — 30 Participants
N/A N=20 A Study to Examine the Effects of Cosmeceutical Therapy in Subjects Undergoing Full Facial Rejuvenation
Facial Rejuvenation With Neurotoxins and/or Hyaluronic Acid Fillers
Primary: C-GAIS by the PI or Designee — 1.22; 2.13; 1.75; 2.75 units on a scale
Phase 4 N=65 Safety and Efficacy of Azzalure/Dysport, Restylane/Emervel Filler and Restylane Skinbooster Treatment
Aesthetics
Primary: Percentage of Subjects With Improvement in Global Facial Aesthetic Appearance — 66.7; 93.5 percentage of subjects
N/A N=16 Jowl Improvement With Injectable Fillers
Jowls
Primary: Blinded Physician Jawline Rating Scale (JRS) Assessment on Scale of 0 to 4 at Baseline Versus 4 Weeks After Last Injection. — 2.214; 2.071; 1.857; 1.857 score on a scale…
Phase 2 N=10 Botulinum Toxin A Single Blind Split-Face Randomized Pilot Study
Facial Rhytids
Primary: Blinded Assessment: Overall Change in Facial Wrinkles From Baseline to Week 2 as Assessed by a Numeric Rating Scale Based on Pre- and Post-treatment Photographs — -0.21…
N/A N=11 A Prospective Evaluation of Infraorbital Filler Injection
Dermal Filler · Rejuvenation
Primary: Volumetric Change in Infraorbital Treatment Baseline to Each Post-intervention Timepoint Day 14, Day 30, and Day 90 — -0.026; -0.065; -0.108 cc
N/A N=90 A Study to Evaluate Effectiveness and Safety of Hyaluronic Acid (HA) Fillers
Volume Deficiency of the Midface
Primary: Percentage of Participants With Aesthetic Improvement of Midface — 96.8; 100; 97.1 percentage of participants
Phase 3 N=60 Subjects' Satisfaction on Pan Facial Aesthetic Enhancement After Treatment With Azzalure® and the Restylane® Range
Aging
Primary: Subject Satisfaction for the Full Face — 92.9; 7.1 percentage of total subjects
Phase 4 N=61 Safety and Efficacy of Treatment With Azzalure, Restylane/Emervel Filler and Restylane Skinbooster
Facial Aesthetic Treatment
Primary: Number of Subjects With Improvement in Global Facial Aesthetic Appearance at 7 Months (Review of Photographs) — 20; 25 Participants
Phase 4 N=116 Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)
Facial Rhytides · Crow's Feet Lines · Glabellar Lines
Primary: Change From Baseline in Satisfaction With Facial Appearance Overall Using a 10-item Questionnaire — 41.22; 31.70 score on a scale
Phase 4 N=185 Treatment With Botulinum Toxin Type A (BOTOX®) in Chinese Patients With Moderate to Severe Frown Lines
Glabellar Rhytides
Primary: Percentage of Subjects With a ≥ 1-Grade Improvement From Day 1 in the Investigator Assessed Facial Wrinkle Scale of Glabellar Rhytides at Maximum Contraction — 97.1…
N/A N=62 Princess® VOLUME Lidocaine for the Correction of Nasolabial Folds
Nasolabial Fold, Hypoplastic
Primary: NLF-SRS Grade of Nasolabial Folds Change — -1.50 score on a scale
Phase 4 N=250 The Treatment of Glabellar Frown Lines
Glabellar Frown Lines
Primary: Efficacy, Measured as the Percentage of Participants Who Responded to Treatment — 95.7; 99.2 percentage of participants
Phase 3 N=168 JUVÉDERM® VOLUMA® With Lidocaine for Correction of Temple Hollowing in Chinese Population
Temple Hollowing
Primary: Number of Participants With Adverse Events — 23; 59; 1; 2 Participants
Phase 3 N=190 Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines
Glabellar Lines
Primary: The Percentage of Responders at Day 29 Cycle 1 as Measured by Investigator's Live Assessment (ILA) of Glabellar Lines at Maximum Frown: DB Period — 81.6; 0.8 Adjusted…
N/A N=100 Study to Evaluate Safety and Efficacy of Revanesse® Ultra + vs Revanesse® Ultra for Correction of NLF
Nasolabial Fold Correction
Primary: Pain at Injection as Measured by Subject on a 100 mm Visual Analog Scale (VAS) Scale at Time 0 Minutes Post Injection — 26.2; 39.4 VAS
Phase 3 N=381 NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines
Glabellar Frown Lines
Primary: Responder by Independent Rater's Assessment at Maximum Frown at Week 4 — 267; 89 participants
N/A N=115 The Volumizing Effect of Juvéderm VOLUMA® in the Mid-Face
Age-related Volume Deficit in the Mid-face
Primary: Subject Experience Measured by Patient Satisfaction Questionnaire — 1.94; 1.62; 1.51 Units on a scale
Phase 4 N=100 A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines
Upper Facial Lines
Primary: Percentage of Participants With Responder Status of 'Mostly Satisfied' or 'Very Satisfied' on the Facial Line Satisfaction Questionnaire (FLSQ) Follow Up Item 4…